MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia (Nasdaq: MTVA), a clinical-stage biotech focused on cardiometabolic diseases, will present an update on its pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET.

Rhea-AI Summary

MetaVia (Nasdaq: MTVA), a clinical-stage biotech focused on cardiometabolic diseases, will present an update on its pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET.

The virtual event will feature a presentation by senior management followed by a Q&A session, with an archived webcast available later on MetaVia's website.

Argus Jun 4 session

-8.58% close to close Open Argus

Details

News Market Reaction – MTVA

On Jun 4, the day this news came out, MTVA closed 8.58% below the previous close.

Data tracked by StockTitan Argus for the Jun 4 session.

Key Figures

Conference date: June 11, 2026 Presentation time: 3:25 pm ET

Conference date

June 11, 2026

Emerging Growth Conference presentation date

Presentation time

3:25 pm ET

Scheduled time for MetaVia conference presentation

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Phase 1 obesity data

   24h Move

   +12.5%

   Higher-dose Phase 1 DA-1726 results with weight and liver improvements in obesity.

2. May 20

   Preclinical MASH data

   24h Move

   +47.9%

   Peer-reviewed vanoglipel data supporting anti-fibrotic activity and biomarker benefits.

3. May 18

   Conference presentation plan

   24h Move

   +0.0%

   Announcement of three late-breaking posters at ADA 2026 on DA-1726 and vanoglipel.

4. May 14

   Q1 2026 earnings update

   24h Move

   -6.7%

   First quarter 2026 financials and updates on DA-1726 and vanoglipel programs.

5. May 11

   EASL poster announcement

   24h Move

   -4.6%

   Planned late-breaking Phase 1 DA-1726 poster at EASL Congress 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present an update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET.

After the presentation, MetaVia's management will open the floor for questions. Attendees may submit questions in advance to questions@emerginggrowth.com, or ask questions live during the event.

Please register using this link to attend the virtual conference and receive event updates. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

If unable to join the event live, an archived webcast will be available on the events page of the MetaVia website.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-conference-302790822.html

SOURCE MetaVia Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will MetaVia (MTVA) present at the Emerging Growth Conference in June 2026?

MetaVia will present at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET. The virtual session will feature an update on its obesity and metabolic therapy pipeline and be followed by a Q&A.

What topics will MetaVia (MTVA) cover at the Emerging Growth Conference presentation?

MetaVia plans to highlight its pipeline of novel obesity and metabolic therapies during the conference. According to MetaVia, the update will focus on cardiometabolic disease programs led by senior management, including its CEO and CFO.

How can investors attend MetaVia's June 11, 2026 Emerging Growth Conference webcast?

Investors can attend by registering via the provided conference link to access the virtual session. Registration enables participation in the live presentation, Q&A segment, and receipt of event updates from organizers.

Will a replay of MetaVia (MTVA) Emerging Growth Conference presentation be available?

Yes, an archived webcast of MetaVia's Emerging Growth Conference presentation will be available on the company’s website events page. This allows investors to review the obesity and metabolic pipeline update after the live event.

How can investors ask questions during MetaVia's Emerging Growth Conference session?

Investors may submit questions in advance to questions@emerginggrowth.com or ask live during the event. According to MetaVia, management will open the floor for questions following the main presentation segment.

How can investors schedule a separate meeting with MetaVia (MTVA) management around the conference?

Investors can request meetings with MetaVia management by contacting Michael Miller at mmiller@rxir.com. This offers an opportunity to discuss the company’s obesity and metabolic therapy pipeline outside the main conference session.